Sandoz acquires cancer-treatment maker

HOLZKIRCHEN, Germany The generics arm of Swiss pharmaceutical company Novartis has completed its acquisition of an Austrian company that makes injectable drugs to treat cancer.

Sandoz announced that it had acquired EBEWE Pharma for $1.3 billion, adding 15 new generic drugs to its portfolio of marketed drugs and more to the pipeline.

“We are delighted to combine EBEWE Pharma’s portfolio and pipeline of high-quality injectables with our global leadership in biopharmaceuticals, anti-infectives and other innovative technologies,” Sandoz CEO Jeff George said in a statement. “This will greatly enhance the range of affordable generic anti-cancer medicines Sandoz offers to patients worldwide.”